Delaware district court rules in favor of acadia in nuplazid® (pimavanserin) formulation patent litigation

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the u.s. district court for the district of delaware ruled in favor of acadia regarding its ‘721 formulation patent for nuplazid® (pimavanserin), acadia's drug for the treatment of parkinson's disease psychosis. in today's order, the court ruled in favor of acadia on both infringement and validity arguments in its formulation patent litigation against aurobindo pharma limited and other anda (abbreviated.
ACAD Ratings Summary
ACAD Quant Ranking